Rhinitis epidemiology and demographics
|
Rhinitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rhinitis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Rhinitis epidemiology and demographics |
|
Risk calculators and risk factors for Rhinitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fatimo Biobaku M.B.B.S [2]
Overview
Rhinitis is a very frequent and highly prevalent global disease, and it is one of the most common conditions presenting for medical care in developed countries.[1]
Epidemiology and Demographics
Rhinitis is a very common disease with significant financial impact on the society.[2] Chronic rhinitis is one of the commonest problems seen by physicians.[1] Allergic rhinitis is estimated to affect one in every six Americans, and it is the fifth most chronic disease in the U.S.[3] Allergic rhinitis is the most common chronic disease in the pediatric age group in the U.S,[3] and it was the most common diagnosis reported in the 2000 Otolaryngology Workforce study.[4] The estimated prevalence of allergic rhinitis ranges from 9-42%.[5] Annually, between 30-60 million people in the U.S suffer from allergic rhinitis, 10-30% of these individuals are adults, and up to 40% are children.[1] The prevalence of allergic rhinitis has been found to be increasing in countries worldwide, and factors such as increased airborne pollution, a rise in the population of dust mite in inadequately ventilated offices/homes with central heating/air conditioning, and sedentary lifestyles, have been suggested to contribute to the rise in its prevalence.[6][7] The prevalence of allergic rhinitis has significantly increased during the past 50 years, with over 50% of adolecents in some countries reporting symptoms of allergic rhinitis.[7] Nonallergic rhinitis is also very common, and it has been estimated to affect about 19 million people in the U.S.[5] Nonallergic rhinitis is predominantly seen in females, and the onset is often after the age of 20 years.[5] There is sometimes an overlap between allergic and nonallergic rhinitis, referred to as "mixed rhinitis", and this has been estimated to affect about 26 million individuals in the United States.[5] Primary atrophic rhinitis is more prevalent in developing countries with warm climates, and it is seen more commonly in young to middle-aged adults.[8]
References
- ↑ 1.0 1.1 1.2 Romeo, Jonathan; Dykewicz, Mark (2014). "Chapter 9:Differential Diagnosis of Rhinitis and Rhinosinusitis". Diseases of the Sinuses. Springer New York. pp. 133–152. ISBN 978-1-4939-0265-1.
- ↑ Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA; et al. (2008). "The diagnosis and management of rhinitis: an updated practice parameter". J Allergy Clin Immunol. 122 (2 Suppl): S1–84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
- ↑ 3.0 3.1 Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR; et al. (2015). "Clinical practice guideline: allergic rhinitis executive summary". Otolaryngol Head Neck Surg. 152 (2): 197–206. doi:10.1177/0194599814562166. PMID 25645524.
- ↑ Mims JW (2014). "Epidemiology of allergic rhinitis". Int Forum Allergy Rhinol. 4 Suppl 2: S18–20. doi:10.1002/alr.21385. PMID 25182349.
- ↑ 5.0 5.1 5.2 5.3 Settipane RA, Charnock DR (2007). "Epidemiology of rhinitis: allergic and nonallergic". Clin Allergy Immunol. 19: 23–34. PMID 17153005.
- ↑ Schoenwetter WF, Dupclay L, Appajosyula S, Botteman MF, Pashos CL (2004). "Economic impact and quality-of-life burden of allergic rhinitis". Curr Med Res Opin. 20 (3): 305–17. doi:10.1185/030079903125003053. PMID 15025839.
- ↑ 7.0 7.1 Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A; et al. (2008). "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)". Allergy. 63 Suppl 86: 8–160. doi:10.1111/j.1398-9995.2007.01620.x. PMID 18331513.
- ↑ Dykewicz MS, Hamilos DL (2010). "Rhinitis and sinusitis". J Allergy Clin Immunol. 125 (2 Suppl 2): S103–15. doi:10.1016/j.jaci.2009.12.989. PMID 20176255.